Delandistrogene Moxeparvovec Gene Therapy in Individuals with Duchenne Muscular Dystrophy Evidence in Focus - AAN | Cliniscan
Cliniscan
Solutions
Tarifs
Ressources
Se connecter
Essayer gratuitement
Cliniscan
Retour aux recommandations
AAN
2025
·
USA
·
Neurology
Delandistrogene Moxeparvovec Gene Therapy in Individuals with Duchenne Muscular Dystrophy Evidence in Focus
Document
Analyser ce document
